Skip to Content

Generic Lo Minastrin Fe Availability

Lo Minastrin Fe is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):

LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate - tablet, chewable, tablet;oral)

  • Manufacturer: APIL
    Approval date: July 24, 2013
    Strength(s): 0.01MG,0.01MG,N/A;1MG,N/A,N/A [RLD]

Has a generic version of Lo Minastrin Fe been approved?

No. There is currently no therapeutically equivalent version of Lo Minastrin Fe available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lo Minastrin Fe. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Chewable oral contraceptive
    Patent 6,667,050
    Issued: December 23, 2003
    Inventor(s): Roger M.; Boissonneault & Tina M.; deVries
    Assignee(s): Galen (Chemicals) Limited
    The present invention relates to a chewable, palatable oral contraceptive tablet, comprising an oral contraceptive agent, a chewable carrier suitable for human consumption, and not comprising a ferrocene compound, as well as use of these tablets in a method of human female oral contraception, and in a method of enhancing compliance with a human female oral contraceptive regimen.
    Patent expiration dates:
    • April 6, 2019
      ✓ 
      Patent use: PREVENTION OF PREGNANCY
      ✓ 
      Drug product
  • Extended estrogen dosing contraceptive regimen
    Patent 7,704,984
    Issued: April 27, 2010
    Inventor(s): Boissonneault; Roger M.
    Assignee(s): Warner Chilcott Company, LLC
    A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.
    Patent expiration dates:
    • February 2, 2029
      ✓ 
      Patent use: PREVENTION OF PREGNANCY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide